This post was originally published on this site

[unable to retrieve full-text content](RTTNews) – Takeda Pharmaceutical Company Limited (TAK), on Monday, said interim analysis from its ongoing phase IIIb open-label extension study of subcutaneous Entyvio in adults with moderately to …